Human Papillomavirus in Young People Epidemiological Research 3
Launched by MONASH UNIVERSITY · Oct 17, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The HYPER3 study is researching how common Human Papillomavirus (HPV) is among young gay and bisexual men aged 16 to 20 years in Australia. This group is particularly at risk for anal cancer, especially those living with HIV. The study aims to find out how many of these young men have anal, genital, and oral HPV. Participants will need to fill out a questionnaire and provide samples for HPV testing, but they won't have to return for any follow-up visits.
To join the study, participants must be male, aged 16 to 20, identify as same-sex attracted, and have lived in Australia since 2018. One important thing to note is that participants need to be comfortable completing the study requirements in English. This study is crucial in understanding HPV's impact and helping improve health strategies for young men at risk.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Men aged 16 to 20 (i.e. men aged 16-18 years in 2023; men aged 16-19 years in 2024; and men aged 16-20 years in 2025 will be recruited. This is to ensure these men would have been eligible for the 9-valent school-based HPV program)
- • Same-sex attracted
- • Residing in Australia since 2018
- Exclusion Criteria:
- • Unable to complete all study requirements in English
About Monash University
Monash University, a leading research institution located in Melbourne, Australia, is dedicated to advancing health and medical knowledge through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, Monash University leverages its extensive expertise in fields such as medicine, pharmacy, and biomedical sciences to conduct rigorous, ethically sound research aimed at improving patient outcomes. The university is committed to fostering a research environment that supports the translation of scientific discoveries into practical applications, ensuring that its clinical trials contribute meaningfully to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Melbourne, Victoria, Australia
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials